our novel dual KRAS G12C inhibitor, and move our second development candidate, FMC-220, a first-in-class covalent p53 Y220C activator, closer to the clinic,” said Chris Varma, Ph.D., chairman ...

In addition, mutations are frequently detected in proteins such as p53, KRAS and APC (adenomatosis polyposis coli), which are intrinsically difficult to modulate with low-molecular-weight inhibitors.

Its research pipeline targets six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC, with the aim of becoming a global leader in drug research and development.

The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.

FMC-220 represents a groundbreaking advancement, with the potential to provide transformative benefits for patients with tumors harboring an important mutant of p53. Preclinical studies ...

"This is an exciting and transformational year for Frontier Medicines as we look forward to interim clinical data for FMC-376, our novel dual KRAS G12C inhibitor, and move our second development ...